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Whereas locked nucleic acid (LNA) has been extensively used to control gene expression, it has never been exploited to control Candida
virulence genes. Thus, the main goal of this work was to compare the efficacy of five different LNA-based antisense oligonucleotides (ASO)
with respect to the ability to control EFG1 gene expression, to modulate filamentation and to reduce C. albicans virulence. In vitro, all LNA-
ASOs were able to significantly reduce C. albicans filamentation and to control EFG1 gene expression. Using the in vivo Galleria
mellonella model, important differences among the five LNA-ASOs were revealed in terms of C. albicans virulence reduction. The inclusion
of PS-linkage and palmitoyl-2′-amino-LNA chemical modification in these five LNA gapmers proved to be the most promising combination,
increasing the survival of G. mellonella by 40%. Our work confirms that LNA-ASOs are useful tools for research and therapeutic
development in the candidiasis field.
© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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(ASOs) to target a specific gene involved in diseases by means of
RNA-targeting, which can lead to inhibition of gene expression
and thus to a blockage in the transfer of genetic information from
DNA to protein.1 ASOs are short oligonucleotides designed to
bind target RNA through standard Watson–Crick base pairing.1
ASOs are often chemically modified in order to protect them
against the action of nucleases, thus improving its biodistribu-
tion, RNA-affinity and potency.2 The phosphorothioate (PS)
backbone was one of the early developed chemical modifica-
tions, and it is characterized by the substitution of one of the non-
bridging phosphate oxygen atoms by a sulfur atom (Figure
S1).1,3,4 The locked nucleic acid (LNA) is a sugar modification⁎ Corresponding author at: LIBRO-Laboratório de Investigação em Biofilmes R
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1549-9634/© 2021 The Author(s). Published by Elsevier Inc. This is an open acchaving, relative to native RNA, a methylene bridge between the
2′-oxygen and 4′-carbon atoms of the ribose sugar (Figure
S1).5,6 A derivative of LNA, named palmitoyl-2′-amino-LNA
resulting from the inclusion of an N-palmitoylated nitrogen atom
in the 2′-position of the ribose ring, has been developed7,8 and
shown to display similarly high-affinity binding as LNA to
complementary RNA and DNA (Figure S1).2,7,9
Candidiasis is the primary fungal infection, with a mortality
rate of about 40%10 and high costs associated in hospitalized
patients.10,11 Candida albicans remains the most prevalent of all
Candida species in the world, with a range of incidence of
approximately 50%.10 C. albicans pathogenicity is attributed to
certain virulence factors, such as its ability to switch from yeastosário Oliveira, CEB-Centre of Biological Engineering, University of Minho,
ess article under the CC BY license (http://creativecommons.org/licenses/by/
Table 1
Sequence of anti-EFG1 LNA-gapmer ASOs, with the respective length.
DNA locked nucleic acid (LNA) palmitoyl-2′-amino-LNA phosphodiester (PO) phosphorothioate (PS).
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regulator gene of C. albicans filamentation,16–19 and we recently
proved that it is an important target to control C. albicans
filamentation.20 As a consequence of the rising levels of C.
albicans resistance to the traditional antifungal therapies (e.g.
fluconazole),13,21 new alternative therapies, with novel mech-
anisms of action, enhanced therapeutic potential, improved
pharmacokinetics, and lower toxicity, are urgently needed to
reach the marketplace to control C. albicans infections. Despite
the use of nucleic acid mimics to detect Candida species,22–24
the application of ASOs to treat Candida infections is still scarce
and it is limited to the first (PS)25 and the second (2’OMe)20
generation of ASOs.
Thus, the main goal of this work was to evaluate the ability of
a set of LNA-ASOs, in the so-called gapmer constitution, to
control EFG1 gene expression and to reduce C. albicans
filamentation (in vitro). The ability of the LNA-ASOs to control
C. albicans virulence in an in vivo model (G. mellonella) was
also assessed.
Methods
Design and synthesis of anti-EFG1 LNA-gapmers
Five LNA-gapmers were designed against the C. albicans
EFG1 (gene orf19.610) target using the sequence 5′-
AATAACGGTATGCC-3′ as starting point20 for the inclusion
of LNA nucleotide modifications. LNA-gapmer1 was used as the
standard ASO during this study, and four additional LNA-
gapmers were subsequently designed by shortening the central
DNA-nucleotide gap (LNA-gapmer2), adding PS-linkages
(LNA-gapmer3 and LNA-gapmer5), and adding a palmitoyl-
2′-amino-LNA modification (LNA-gapmer4 and LNA-gap-
mer5) (Table 1). In all LNA-gapmer designs, three LNA
nucleotides were introduced consecutively at both 3′ and 5′ends to increase the ASOs stability. Furthermore, in order to
ensure compatibility with RNase H-mediated cleavage of the
target RNA upon binding, the central regions (gap) were
constituted of DNA nucleotides.26 Finally, a scrambled PS
LNA-gapmer control was synthesized with three mismatches
within the gap (Table 1).
The LNA-gapmers were synthesized using the standard
phosphoramidite method on an automated nucleic acid synthe-
sizer (PerSpective Biosystems Expedite 8909 instrument). All
standard oligonucleotides were purchased from Integrated DNA
Technologies (Leuven, Belgium). LNA phosphoramidites were
purchased from Qiagen, and the synthesis was performed in 1.0
μmol scale using an LNA T 40 custom primer support (GE
Healthcare). LNA phosphoramidites were incorporated accord-
ing to the following conditions: trichloroacetic acid in CH2Cl2 as
detritylation reagent; 0.25 M 4,5-dicyanoimidazole (DCI) in
CH3CN as an activator; acetic anhydride in THF (9:91; v/v) as
capA solution; N-methylimidazole in THF (1:9; v/v) as capB
solution; and a thiolation solution containing 0.2 M phenylacetyl
disulfide (PADS) in 3-picoline/CH3CN (1:1, v/v) for 180 s. The
coupling yields were based on the absorbance of the dimethox-
ytrityl cation (DMT+) released after each coupling step.
Palmitoyl-2′-amino-LNA phosphoramidite monomer was incor-
porated by manual-coupling7 using 5-[3,5-bis(trifluoromethyl)
phenyl]-H-tetrazole (0.25 M, in anhydrous acetonitrile) as an
activator and extended coupling time (20 min). After the
synthesis process, the LNA-gapmers were cleaved from the
solid support and the protecting groups removed by treatment
with a 1:1 mixture (v/v) of 98% aqueous methanol (v/v) and a 7
M solution of ammonia in methanol for 2 h at room temperature
followed by treatment with 32% aqueous ammonia (w/w) at 55
°C for 12 h. The ASOs were characterized by ion-exchange
HPLC (IE-HPLC, Lachrom) (Figure S2) and matrix-assisted
laser desorption ionization time-to-flight mass spectrometry
(MALDI-TOF, Microflex LT, Bruker, Daltonies) (Figure S3).
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(w/w) aqueous solution of acetic acid for 20 min at room
temperature, precipitated by the addition of ice-cold acetone, and
characterized by IE-HPLC (purity >90%) and MALDI-TOF
mass spectrometry (confirmation of composition).
Characterization of anti-EFG1 LNA-gapmers
Melting temperatures (Tm values)
The Tm values determined for duplexes involving RNA
complementary strands were measured on a PerkinElmer
Lambda 35 UV/VIS spectrometer equipment with Peltier
Temperature Programmer (PTP6). The concentration of each
oligonucleotide was determined optically at 260 nm using their
molar extinction coefficients (134,000 L per M−1 cm−1 of
strands). All measurements were performed in medium salt
buffer with 220 mM Na+ (composition: 200 mM NaCl, 20 mM
NaH2PO4 and 0.1 mM EDTA, pH 7.0). The LNA-gapmer ASOs
were mixed with the corresponding unmodified complementary
strand at a 1:1 ratio (2.5 nmol of each strand). All melting curves
for duplex denaturation were collected at a 260 nm wavelength
as a function of temperature in the range from 8 to 80 °C (heating
rate of 1 °C per min) (Figure S4). The values of Tm were
determined as an average of two individual measurements.
Secondary structure
The secondary structure of the LNA-gapmers was determined
by circular dichroism (CD) studies. The spectra were recovered
on a JASCO DC 1500 spectrophotometer using cuvettes with 0.1
cm path length and averaged over three scans (320-200 nm, 50
nm min−1 intervals, 1 nm bandwidth, and 1 s response time) and
with a background corrected using the buffer applied (5 mM
MgCl2, 10 mM NaCl and 1 mM sodium phosphate). The LNA-
gapmer ASOs were used in the following constitution, i.e., 50
μM RNA, 5 mM MgCl2, 10 mM NaCl, and 1 mM sodium
phosphate-pH 7.2. All other strands were prepared using 25 μM
of each RNA using the same buffer. Hybridization step was
performed by heating to 90 °C for 5 min followed by slow
cooling to room temperature followed by spectral recording.
Anti-EFG1 LNA-gapmers cytotoxicity
The cytotoxicity of the LNA-gapmers was determined using a
3T3 cell line (Fibroblasts, Embryonic tissue, Mouse from CCL3,
American Type Culture Collection) according to the
ISO10993:5.27 For that, 3T3 cells were grown in Dulbecco's
Modified Eagle's Medium (DMEM, Biochrom, Germain)
supplied by 10% of fetal bovine serum (FBS, Sigma Aldrich)
and 1% of antibiotic-containing penicillin and streptomycin (P/
S) (Biochrom, Germain). After detachment, a suspension with 1
× 105 cells ml−1 was added to a 96-well plate and cells were
allowed to grow until attaining 80% confluence. Different
concentrations of each LNA-gapmer (10, 40 and 100 nM) were
prepared in DMEM medium and 50 μL of each concentration
was added to each well. The positive control was prepared by
adding 50 μL of DMEM medium and the negative control by
adding 50 μL of DMSO to the cells. The plates were incubated
for 24 h at 37 °C and 5% CO2.
After the incubation period, 10 μL of a solution of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium (MTS, CellTiter 96® Aqueous One
Solution Cell Proliferation Assay, Promega) and 1% of D-MEM
without phenol was added to each well, and the resulting mixture
was incubated for 1 h at 37 °C. The absorbance for each well was
measured at 490 nm in a microplate reader (Biochrom EZ Reader
800 Plus, Cambridge, England).
Anti-EFG1 LNA-gapmers performance in vitro
Microorganisms and growth conditions
The Candida strain used in this study was C. albicans
SC5314, a Candida collection reference strain from the Biofilm
group of the Centre of Biological Engineering (Braga, Portugal).
The strain identification was confirmed using a chromogenic
medium, CHROMagar™ Candida, through the distinction of
colony colors and PCR-based sequencing with primers for TS1
and ITS4.28
For all experiments, the yeast strain was subcultured on
Sabouraud dextrose agar (SDA; Merck, Germany) and incubated
for 24 h at 37 °C. Cells were then inoculated in Sabouraud
dextrose broth (SDB; Merck, Germany) and incubated overnight
at 37 °C, 120 rpm. After incubation, the cells' suspensions were
centrifuged for 10 min, at 3000 ×g and 4 °C, and washed twice
with phosphate-buffered saline solution (PBS; pH 7, 0.1 M).
Pellets were suspended in 5 ml of Roswell Park Memorial
Institute 1640 medium (RPMI; pH 7; Sigma, St Louis, USA),
and the cellular density was adjusted for each experiment using a
Neubauer chamber (Marienfild, Land-Konicshofem, Germany)
to 1 × 106 cells ml−1. All experiments were performed in
triplicate, and at least three independent assays were run.
Effect on filamentation
To evaluate the effect of the LNA-gapmers on C. albicans
filamentation, yeast cells were incubated with each ASO for 24 h
in an Erlenmeyer flask. For that, 5 mL of each LNA-gapmer at 40
nM (prepared on RPMI) was added to 5 mL of C. albicans
suspension at 1 × 106 cells ml−1 (prepared on RPMI). The
suspensions were incubated at 37 °C under gentle agitation (120
rpm). The positive control was prepared with 10 mL of the same
yeast cell concentration on RPMI. In addition, the LNA-
scrambled gapmer was also incubated with C. albicans for 24
h (as negative control). After 24 h, aliquots were recovered, and
filaments were counted using a Neubauer chamber. The results
were presented as percentage (%) of filamentation reduction
through the following formula:
%filamentation inhibition
¼ %filamented cells on control−%filamented cells on treated sampleð Þ
%filamented cells on control
In parallel, the levels of filamentation and the length of the
filaments were confirmed through fluorescence microscopy
(Olympus BX51) coupled with a DP71 digital camera and the
filter used was DAPI 360-370/420 (Olympus Portugal SA, Porto,
Portugal). C. albicans cells were stained with 1% (v/v) of
calcofluor (Sigma-Aldrich, St. Louis, MO, USA) for 15 min in
dark conditions, centrifuged for 5 min, and washed twice with
ultra-pure water. Images were acquired with the program
FluoView FV100 (Olympus). The filaments' length was
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software.
Effect on EFG1 gene expression
Reverse transcription-qPCR (qRT-PCR) was used to deter-
mine the effect of LNA-gapmers on EFG1 gene expression.
After 24 h of incubation, 1 mL of each suspension was collected,
subjected to centrifugation for 5 min at 6000 ×g and 4 °C, and
then washed once with PBS. RNA extraction was performed
using the PureLink RNA Mini Kit (Invitrogen, Carlsbad, CA,
USA).20 To avoid potential DNA contamination, samples were
treated with DNase I (Deoxyribonuclease I, Amplification
Grade, Invitrogen) and the RNA concentration was determined
by optical density measurement (NanoDrop 1000 Spectropho-
tometer Thermo Scientific®). The complementary DNA (cDNA)
was synthesized using the Xpert cDNA Synthesis Mastermix
(Grisp, Porto, Portugal) in accordance with the manufacturer's
instructions, and qRT-PCR (CFX96, Biorad) was performed on a
96-well microtiter plate using Eva Green Supermix (Biorad,
Berkeley, USA). Each reaction was performed in triplicate and
mean values of relative expression were determined by the 2
−ΔΔCq method. The expression of the EFG1 gene was normalized
using the ACT1 Candida reference gene.29 Non-transcriptase
reverse (NRT) controls were included in each run. The primers
were designed using the Primer 3 web-based (Table S1).
Anti-EFG1 LNA-gapmers performance in vivo
The Galleria mellonella caterpillar infection model was used
for the in vivo studies as previously described by Mil-Homens et
al.30,31 G. mellonella larvae were reared on a pollen grain and
bee wax diet at 25 °C in the darkness, and a micro syringe was
adapted into a micrometer range so as to control the injection
volume into hemolymph of larvae.
Toxicity evaluation
To test toxicity of the anti-EFG1 LNA-gapmers in vivo, 10
G. mellonella larvae were injected, via the hindmost left proleg
previously sanitized with 70% (v/v) ethanol, with 5 μL of two
distinct concentrations (40 and 100 nM both prepared with PBS)
of each LNA-gapmer. As control, a set of larvae was injected
with the same volume of PBS. Larvae were placed in Petri dishes
and stored in the dark at 37 °C. Larvae survival was recorded
over 4 days, and survival curves were constructed.
Galleria mellonella survival
To study the effect of the LNA-gapmers on G. mellonella
survival rate, larvae were injected with C. albicans and each
LNA-gapmer. The concentration of C. albicans to be injected (7
× 107 cells mL−1) was selected on the basis of the G. mellonella
lethality results after injection with different concentrations of
yeast cells (between 7 × 107 cells mL−1 and 2 × 108 cells mL−1)
(data not shown). Next, 10 larvae were injected with 5 μL of a
suspension of C. albicans at 7 × 107 cells mL−1 mixed with 40
nM of each LNA-gapmer. Larvae were placed in Petri dishes and
stored in the dark at 37 °C for 3 days, whereupon survival curves
were constructed. Caterpillars were considered dead when they
displayed no movement in response to a touch with tweezers.
Histological analysis of G. mellonella fat bodies was also
performed to evaluate the effects of LNA-gapmers on C.albicans filamentation. For each condition, two larvae were
recovered after pre-determined times (24 h and 48 h) and their fat
bodies were removed through an incision in the midline of the
ventral with a scalpel blade. The fat bodies were stored in 4% (v/
v) paraformaldehyde at 4 °C to prepare for histological
processing. The tissue was mounted in paraffin blocks and cut
in sections of 4-5 μm, which were stained with hematoxylin–
eosin (HE) and periodic acid Schiff (PAS).32,33 The yeast and
hyphae of C. albicans were observed under a light microscope.
For analysis of filamentation, all areas of the histological section
stained with PAS that contained hyphae and yeast cells were
photographed with an OLYMPUS BX51 microscope coupled
with a DP71 digital camera (Olympus Portugal SA, Porto,
Portugal).Statistical analysis
Data are expressed as the mean ± standard deviation (SD) of a
least three independent experiments. Results were compared
using two-way analysis of variance (ANOVA). All tests were
performed with a confidence level of 95%. Kaplan–Meier
survival curves were plotted and differences in survival were
calculated by using log-rank Mantel–Cox statistical test. All
performed with GraphPad Prism 6® (CA, USA).
Results
Characterization of anti-EFG1 LNA-gapmers
Figure 1 represents the results of the secondary structure for
single-stranded (ss) and double-stranded(ds)-LNA:RNA com-
pounds. All duplexes presented a similar overall conformation,
thus indicating no major alterations in secondary structure. For
single-strands, all LNA-gapmers present bands as expected from
literature observations,34,35 i.e. low positive bands around 270
nm and 220 nm and low negative bands around 240 nm and 210
nm. The dsRNA, defined as A-duplex, is characterized by a
strong positive band at 270 nm coupled with a strong negative
band at 210 nm,34,36,37 as it can be seen for dsLNA:RNA in all
LNA-gapmers.
Table 2 and Figure S4 show the values of Tm measured for all
LNA-gapmers with RNA complement. The LNA-gapmer1
presented a Tm of 70 °C and similarly, the LNA-gapmer2
(exclusion of one nt) presented a Tm of 72 °C. In contrast, LNA-
gapmer3 (addition of PS-linkages), LNA-gapmer4 (addition of
the palmitoyl-2′-amino-LNA modification) and LNA-gapmer5
(addition of PS-linkages and the palmitoyl-2′-amino-LNA
modification) showed a significant decrease in Tm for 63 °C,
65 °C and 56 °C, respectively.Cytotoxicity of anti-EFG1 LNA-gapmers
The in vitro cytotoxicity was assessed on 3T3 cells and using
different concentrations of LNA-gapmers (10, 40 and 100 nM)
(Figure 2). These results show that all LNA-gapmers are non-
cytotoxic in concentrations up to 40 nM, as the relative 3T3 cells
viability was >70% under these conditions.27
Table 2
Characterization of anti-EFG1 LNA-gapmer ASOs. The thermal
denaturation temperatures (Tm values, °C) of the LNA-gapmer ASOs were
determined in medium salt buffer against its RNA complement. All melting
curves were collected at a 260 nm wavelength as a function of temperature in
the range from 8 to 80 °C (heating rate of 1 °C per min).







Figure 1. Studies of characterization of anti-EFG1 LNA-gapmer ASOs. Evaluation of the secondary ASOs structure by circular dichroism spectral analysis of
single-strands (ssLNA) and double-stranded complexes (dsLNA:RNA; dsLNA:DNA). The spectra were recorded in a 0.1 cm path length cuvette. Each spectrum
was recorded from the averaged over three scans (320-200 nm, 50 nm min−1 intervals, 1 nm bandwidth, and 1 s response time).
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Based on the cytotoxicity results, the ASO concentration of
40 nM was selected for the in vitro experiments. The effect of all
LNA-gapmers on C. albicans filamentation and on the EFG1
gene expression was evaluated after 24 h of treatment. To note,
the C. albicans strain used under this study presents a highFigure 2. Studies of cytotoxicity of anti-EFG1 LNA-gapmer ASOs. Relative
cell viability (%) determined by the absorbance (Abs (490 nm) cm−2) of
formazan product obtained from 3T3 cell line, treated with different
concentrations of LNA-gapmers (10, 40, 100 nM). The control is compared
to cells without ASO treatment.filamentation capacity (Figure S5, A) together with high levels of
EFG1 gene expression (Figure S5, B). Figure 3, A shows that all
LNA-gapmers were able to control C. albicans filamentation
with values of inhibition greater than 40%. The LNA-gapmer1
was capable to reduce around 45% of C. albicans filamentation,
and this reduction increased for all other LNA-gapmers, however
without statistically significant differences (P value > 0.05). The
LNA-gapmer2 was able to reduce into 50% C. albicans
filamentation and the LNA-gapmer3-5 into 55% (Figure 3, A).
The results revealed that the LNA-gapmers modified with PS-
linkages and the palmitoyl-2′-amino-LNA display a similar in
vitro performance. To note, the LNA-scrambled ASO tested was
unable to reduce C. albicans filamentation (Figure S6).
Figure 3, B shows that all LNA-gapmers were able to reduce
the levels of EFG1 gene expression with values also greater than
40%. LNA-gapmer1 was able to reduce the levels of EFG1
expression by approximately 74%. Moreover, the LNA-gapmer2
and LNA-gapmer3 had a similar performance to LNA-gapmer1,
with reductions of approximately 78% and 71%, respectively.
Concerning the LNA-gapmer4 and LNA-gapmer5, the levels of
gene inhibition were slightly reduced, reaching around 44% and
61%, respectively. It is important to note that the results were
statistically significant when comparing the performance of all
LNA-gapmers with the untreated cells (P value < 0.05), despite
not presenting statistically significant differences among the
LNA-gapmers (P value > 0.05).
The epifluorescence microscopy images (Figure 3, C)
corroborate the results in the number of C. albicans' filaments
decrease (Figure 3, A), also demonstrating its ability to reduce
the filament length. Concerning this issue, the highest impact
was observed with the LNA-gapmer3 and LNA-gapmer5,
achieving values of reduction of around 65% and 56%,
respectively.
Anti-EFG1 LNA-gapmers performance in vivo
The in vivo effects of the anti-EFG1 LNA-gapmer ASOs
were evaluated using the G. mellonella model38 (Figure 4).
Notably, experiments showed the absence of in vivo toxicity for
all the LNA-gapmers (40 nM) (Figure 4, A).
To evaluate the performance of the LNA-gapmers in vivo, G.
mellonella larvae were injected with a lethal dose of C. albicans
(7 × 107 cells/mL) together with 40 nM of each LNA-gapmer. As
Figure 3. Performance of anti-EFG1 LNA-gapmer ASOs in vitro. Effect of treatment of C. albicans with LNA-gapmers (40 nM) during 24 h. (A) Percentage of
C. albicans filamentation reduction determined by microscopic observation. As control, the C. albicans cells were prepared only in RPMI (without ASOs). (B)
Levels of EFG1 gene expression evaluated by qRT-PCR. Untreated represents an experiment prepared only with cells on RPMI (without ASOs). (C)
Epifluorescence microscopy image analysis of C. albicans cells stained with calcofluor. The number in each image refers to the average length of filaments. The
arrows highlight the C. albicans in yeast morphology. Error bars represent standard deviation. *Significant differences between the untreated cells and the LNA-
gapmers tested (P < 0.05).
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albicans cells (control) only 57% at 24 h, 33% at 48 h and 20% at
72 h of larvae were alive. It is important to underline that the
treatment with all LNA-gapmers increased the G. mellonella
survival rate. The larvae injection with the LNA-gapmer1 and
LNA-gapmer2 increased the survival, respectively, to 80% and
67% at 24 h and to 53% and 47% at 48 h, with no effect observed
at 72 h (with 20% of survival in control and with both LNA-
gapmers). The treatment of larvae with the LNA-gapmer3 and
LNA-gapmer4 displayed an increase in the survival rate of
approximately 90% and 83% at 24 h, 60% at 48 h and 30% and
33% at 72 h, respectively. The most promising of all LNA-gapmers was the LNA-gapmer5, which induced a survival rate of
around 93% at 24 h, 77% at 48 h and 60% at 72 h.
In parallel, the fat body of larvae (Figure S7) was recovered
and processed for histological analysis (Figure 4, C). As
illustrated, yeast's cells are organized into clusters located
around the organs or scattered around the adipose tissue.
Sections of larvae infected only with C. albicans (control)
showed intense C. albicans clusters composed mostly of
filamentous forms, with a significant increase in tissue area
engaged by hyphae from 24 h to 48 h post infection. Larvae
sections treated with LNA-gapmer4 and LNA-gapmer5 revealed
a notable decrease in the number of C. albicans as filamentous
Figure 4. Performance of anti-EFG1 LNA-gapmer ASOs in vivo. (A) Anti-EFG1 LNA-gapmers toxicity evaluation after injection of G. mellonella larvae with
40 nM of each ASO during 96 h. As control larvae were injected only with PBS. (B) Survival curves ofG. mellonella larvae infected with C. albicans SC5314 (7
× 107 cells mL−1 injected per larva) and treated with each LNA-gapmer (40 nM) during 72 h. Larvae were infected with a single dose of each LNA-gapmer at the
same time of C. albicans cells and as control infected larvae were only injected with PBS. (C) Histological sections of the fat bodies of G. mellonella infected
with C. albicans and treated with each LNA-gapmer (40 nM) at 24 h and 48 h. The tissues of larvae were stained with PAS coloration. The arrows highlight the
C. albicans in yeast morphology. The magnification was 400×. Results represent means of three independent assays for 10 larvae per treatment. ***Significant
difference between the control (Candida + PBS) and the LNA-gapmer5 (P value < 0.001).
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body invaded by C. albicans.
Discussion
In the last decade, the number of successful applications of
ASOs for the treatment of human diseases39–46 and to manage
virus and bacterial infections47–49 has increased. However, the
ASO technology has been poorly exploited to control Candida
virulence determinants, and to date there are no reports of
applications of LNA chemical modification to control Candida
virulence determinants. Through this work, the efficacy of LNA-
gapmer ASOs, designed to hybridize specifically to an EFG1target, was compared, concerning its ability to control EFG1
gene expression and to reduce C. albicans filamentation, in order
to control in vivo C. albicans virulence. Therefore, a set of five
LNA-gapmers was designed with different lengths and different
chemical modifications, such as the PS-linkages or/and the
palmitoyl-2′-amino-LNA chemical modification/s.
Initially, it was important to confirm the composition and the
purity of all LNA-gapmers (Figures S2 and S3) and to verify if
the inclusion of LNA chemical modifications to the sequence
influences its secondary structure (Figure 1) and its hybridization
stability (Table 2). In many aspects the LNA gapmer ASOs
behaved quite similarly. However, the inclusion of PS-linkages
(LNA-gapmer3) led to a decrease in duplex thermal denaturation
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described in the literature,50 , 51 the inclusion of the PS
modification and the palmitoyl-2′-amino-LNA (LNA-gap-
mer4 and LNA-gapmer5) also reduced the thermal denatur-
ation temperature of the corresponding duplexes when
compared to the thermal denaturation temperatures of the
duplexes involving the reference LNA-gapmer1. Of all LNA-
gapmers characterized, LNA-gapmer5 displayed the lowest
affinity. The decrease in thermal denaturation temperature
upon incorporation of the palmitoyl-2′-amino-LNAmonomers
corresponds with results reported earlier.8
The in vitro and in vivo efficacy of each LNA-gapmer was
evaluated at 40 nM since none of them presented in vitro (Figure
2) or in vivo toxicity (Figure 4, A). The in vitro results
demonstrate the capacity of the LNA-gapmers to control EFG1
gene expression by 40%-60% (Figure 3, B) and C. albicans'
filamentation around 50% (Figure 3, A), as well as the filaments
length on 60% (Figure 3, C). The inclusion of PS-linkages
(LNA-gapmer3) enhanced filamentation reduction, however,
without any additional effect on EFG1 gene silencing. On the
other hand, the inclusion of palmitoyl-2′-amino-LNA monomers
on LNA-gapmer4 and LNA-gapmer5 did not significantly
enhance the filamentation control or the gene silencing when
compared to the performance of the other LNA-gapmers. It
should be pointed out that the ability of LNA-gapmer ASOs to
control C. albicans' filamentation and to reduce the filaments'
length is crucial to reduce C. albicans pathogenicity, once it
decreases C. albicans' ability to invade the human body tissues
and to escape of host's immune system.52–54
The G. mellonella caterpillar infection model was used to
evaluate the effects of the LNA-gapmer ASOs on C. albicans
virulence (Figure 4). Interestingly, in contrast to the in vitro
experiments, in vivo results highlight pronounced differences
among the individual LNA-gapmers. Thus, although the LNA-
gapmer5 did not show the best performance in vitro (Figure 3),
this gapmer was the most efficient with respect to the control of
in vivo C. albicans' virulence (Figure 4, B and C). In fact, larvae
treated with LNA-gapmer5 significantly increased G. mellonella
survival from 20% to 60% (at 72 h of treatment). The histological
images corroborated these findings with a notable reduction in
the number of C. albicans filamentous cells and a consequent
reduction in area of G. mellonella invasion (Figure 4, C).
This work revealed that it is possible to design nucleic acid
mimics to control important virulence factors behind the Can-
dida infections. The application of LNA-gapmer ASO confirms
the possibility to control virulence determinants of C. albicans
and thus to control its pathogenicity. Moreover, the LNA-type
gapmer ASOs modifications with PS-linkages and palmitoyl-2′-
amino-LNA monomers are favorable for in vivo performance
and constitute promising lead structures for development of
drugs against Candida species.
However, considering any possible future clinical applica-
tions in the control of local candidiasis (oral, vaginal, and
urinary), as well as of systemic infections (blood), additional
studies are imperative. It will be necessary to investigate
strategies for LNA-gapmer ASO delivery and to extend the in
vivo studies for a more complex and robust model, as a mouse
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